Furthermore, several of these structurally intriguing bis-iridoid glycosides and triterpenoids (2, 8, 17, 29, and 31) demonstrate ACC1 or ACL inhibitory activity, indicating their potential as alternative therapeutic agents for treating metabolic diseases. The gene discussed is ACLY; the disease is metabolic disease.